Associations of the plasma interleukin 6 (IL-6) levels with disability and mortality in the elderly in the Treviso Longeva (Trelong) study

Bethin, 2000, lnterleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation, Proc. Natl. Acad. Sci. USA, 97, 9317, 10.1073/pnas.97.16.9317 Cohen, 1997, The association of plasma IL-6 levels with functional disability in community-dwelling elderly, J. Gerontol. A. Biol. Sci. Med. Sci., 52, M201, 10.1093/gerona/52A.4.M201 Colinet, 2005, A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index, Br. J. Cancer, 93, 1098, 10.1038/sj.bjc.6602836 Di Bari, 2006, Predictive validity of measures of comorbidity in older community dwellers: the “Insufficienza Cardiaca negli Anziani Residenti a Dicomano Study”, J. Am. Geriatr. Soc., 54, 210, 10.1111/j.1532-5415.2005.00572.x Ershler, 2000, Age-associated increased IL-6 gene expression, late-life diseases, and frailty, Annu. Rev. Med., 51, 245, 10.1146/annurev.med.51.1.245 Ferrucci, 1999, Serum IL-6 level and the development of disability in older persons, J. Am. Geriatr. Soc., 47, 639, 10.1111/j.1532-5415.1999.tb01583.x 2002 Gallucci, 2004 Gallucci, 2007, The Treviso Longeva (Trelong) Study: a biomedical, demographic, economic and social investigation on people 70 years and over in a typical town of North-East of Italy, Arch. Gerontol. Geriatr., 44, 173, 10.1016/j.archger.2007.01.025 Harris, 1999, Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly, Am. J. Med., 106, 506, 10.1016/S0002-9343(99)00066-2 Keller, 1996, Molecular and cellular biology of interleukin-6 and its receptor, Front. Biosci., D340, 10.2741/A136 Lawton, 1969, Assesment of older people: self maintaining and instrumental activities of daily living, Gerontologist, 9, 176, 10.1093/geront/9.3_Part_1.179 Parmar, 1995 Path, 2001, Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function, J. Clin. Endocrinol. Metab., 86, 2281, 10.1210/jc.86.5.2281 Perkins, 2004, Common comorbidity scales were similar in their ability to predict health care costs and mortality, J. Clin. Epidemiol., 57, 1040, 10.1016/j.jclinepi.2004.03.002 Volpato, 2001, Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study, Circulation, 103, 947, 10.1161/01.CIR.103.7.947 WHO, (World Health Organization) (1998): International Classification of Diseases, 9th Revision, with Clinical Modifications (ICD-9-CM). ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD-9. Xing, 1998, IL-6 is an antiinfiammatory cytokine required for controlling local or systemic acute inflammatory responses, J. Clin. Invest., 101, 311, 10.1172/JCI1368